Literature DB >> 32100222

Volumetric Histogram Analysis of Apparent Diffusion Coefficient as a Biomarker to Predict Survival of Esophageal Cancer Patients.

Atsushi Hirata1, Koichi Hayano2, Gaku Ohira1, Shunsuke Imanishi1, Toshiharu Hanaoka1, Takeshi Toyozumi1, Kentaro Murakami1, Tomoyoshi Aoyagi3, Kiyohiko Shuto4, Hisahiro Matsubara1.   

Abstract

BACKGROUND: The purpose of this study was to investigate whether histogram analysis of an apparent diffusion coefficient (ADC) can serve as a prognostic biomarker for esophageal squamous cell carcinoma (ESCC).
METHODS: This retrospective study enrolled 116 patients with ESCC who received curative surgery from 2006 to 2015 (including 70 patients who received neoadjuvant chemotherapy). Diffusion-weighted magnetic resonance imaging (DWI) was performed prior to treatment. The ADC maps were generated by DWIs at b = 0 and 1000 (s/mm2), and analyzed to obtain ADC histogram-derived parameters (mean ADC, kurtosis, and skewness) of the primary tumor. Associations of these parameters with pathological features were analyzed, and Cox regression and Kaplan-Meier analyses were performed to compare these parameters with recurrence-free survival (RFS) and disease-specific survival (DSS).
RESULTS: Kurtosis was significantly higher in tumors with lymphatic invasion (p = 0.005) with respect to the associations with pathological features. In univariate Cox regression analysis, tumor depth, lymph node status, mean ADC, and kurtosis were significantly correlated with RFS (p = 0.047, p < 0.001, p = 0.037, and p < 0.001, respectively), while lymph node status and kurtosis were also correlated with DSS (p = 0.002 and p = 0.017, respectively). Furthermore, multivariate analysis demonstrated that kurtosis was the independent prognostic factor for both RFS and DSS (p < 0.001 and p = 0.015, respectively). In Kaplan-Meier analysis, patients with higher kurtosis tumors (> 3.24) showed a significantly worse RFS and DFS (p < 0.001 and p = 0.006, respectively).
CONCLUSIONS: Histogram analysis of ADC may serve as a useful biomarker for ESCC, reflecting pathological features and prognosis.

Entities:  

Year:  2020        PMID: 32100222     DOI: 10.1245/s10434-020-08270-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.

Authors:  Thomas W Rice; Deepa T Patil; Eugene H Blackstone
Journal:  Ann Cardiothorac Surg       Date:  2017-03

2.  Volumetric histogram analysis of apparent diffusion coefficient for predicting pathological complete response and survival in esophageal cancer patients treated with chemoradiotherapy.

Authors:  Atsushi Hirata; Koichi Hayano; Gaku Ohira; Shunsuke Imanishi; Toshiharu Hanaoka; Kentaro Murakami; Tomoyoshi Aoyagi; Kiyohiko Shuto; Hisahiro Matsubara
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

3.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.

Authors:  D Le Bihan; E Breton; D Lallemand; M L Aubin; J Vignaud; M Laval-Jeantet
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

4.  Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?

Authors:  Riccardo De Robertis; Bogdan Maris; Nicolò Cardobi; Paolo Tinazzi Martini; Stefano Gobbo; Paola Capelli; Silvia Ortolani; Sara Cingarlini; Salvatore Paiella; Luca Landoni; Giovanni Butturini; Paolo Regi; Aldo Scarpa; Giampaolo Tortora; Mirko D'Onofrio
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

5.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

6.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Quantifying tumour heterogeneity with CT.

Authors:  Balaji Ganeshan; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-03-26       Impact factor: 3.909

8.  Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results.

Authors:  Takeshi Fujishiro; Kiyohiko Shuto; Koichi Hayano; Asami Satoh; Tsuguaki Kono; Gaku Ohira; Takayuki Tohma; Hisashi Gunji; Kazuo Narushima; Toru Tochigi; Toshiharu Hanaoka; Sayaka Ishii; Noriyuki Yanagawa; Hisahiro Matsubara
Journal:  Oncol Rep       Date:  2014-01-22       Impact factor: 3.906

Review 9.  Improving tumour heterogeneity MRI assessment with histograms.

Authors:  N Just
Journal:  Br J Cancer       Date:  2014-09-30       Impact factor: 7.640

10.  Rim sign and histogram analysis of apparent diffusion coefficient values on diffusion-weighted MRI in triple-negative breast cancer: Comparison with ER-positive subtype.

Authors:  Yangsean Choi; Sung Hun Kim; In Kyung Youn; Bong Joo Kang; Woo-Chan Park; Ahwon Lee
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

View more
  1 in total

1.  A Clinical-Radiomics Nomogram Based on the Apparent Diffusion Coefficient (ADC) for Individualized Prediction of the Risk of Early Relapse in Advanced Sinonasal Squamous Cell Carcinoma: A 2-Year Follow-Up Study.

Authors:  Naier Lin; Sihui Yu; Mengyan Lin; Yiqian Shi; Wei Chen; Zhipeng Xia; Yushu Cheng; Yan Sha
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.